Interfering with lysophosphatidic acid receptor edg2/lpa 1 signalling slows down disease progression in SOD1‐G93A transgenic mice

Author(s):  
Ángela Gento‐Caro ◽  
Esther Vilches‐Herrando ◽  
Victoria García‐Morales ◽  
Federico Portillo ◽  
Guillermo Rodríguez‐Bey ◽  
...  
2021 ◽  
Author(s):  
Shahan Mamoor

In these brief notes we document work using published microarray data (1, 2) to pioneer integrative transcriptome analysis comparing vulvar carcinoma to its tissue of origin, the vulva. We report the differential expression of lysophosphatidic acid receptor 3, encoded by LPAR3, in cancer of the vulva. LPAR3 may be of pertinence to understanding transformation and disease progression in vulvar cancer (3).


MedChemComm ◽  
2015 ◽  
Vol 6 (1) ◽  
pp. 13-23 ◽  
Author(s):  
Inés González-Gil ◽  
Debora Zian ◽  
Henar Vázquez-Villa ◽  
Silvia Ortega-Gutiérrez ◽  
María L. López-Rodríguez

The current status of the LPA1receptor and its ligands in the drug development pipeline is reviewed.


2008 ◽  
Vol 39 (3) ◽  
pp. 342-355 ◽  
Author(s):  
Elisa Matas-Rico ◽  
Beatriz García-Diaz ◽  
Pedro Llebrez-Zayas ◽  
Diana López-Barroso ◽  
Luis Santín ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document